Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial
Alasdair P S Munro1,2, Leila Janani3, Victoria Cornelius3, Parvinder K Aley4,5, Gavin Babbage1, David Baxter6, Marcin Bula7, Katrina Cathie1,2, Krishna Chatterjee8, Kate Dodd7, Yvanne Enever9, Karishma Gokani10, Anna L Goodman11,12, Christopher A Green10, Linda Harndahl13, John Haughney14, Alexander Hicks13, Agatha A van der Klaauw15, Jonathan Kwok16, Teresa Lambe4,5
1NIHR Southampton Clinical Research Facility and Biomedical Research Centre, University Hospital Southampton NHS Foundation Trust, Southampton, UK
2Faculty of Medicine and Institute for Life Sciences, University of Southampton, Southampton, UK
3Imperial Clinical Trials Unit, Imperial College London, London, UK
4Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK
5NIHR Oxford Biomedical Research Centre, Oxford, UK
6Stockport NHS Foundation Trust, Stockport, UK
7NIHR Liverpool and Broadgreen Clinical Research Facility, Liverpool, UK
8NIHR Cambridge Clinical Research Facility, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK
9PHARMExcel. Welwyn Garden City, Hertfordshire, UK
10NIHR/Wellcome Clinical Research Facility, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK
11Department of Infection, Guy's and St Thomas’ NHS Foundation Trust, London, UK
12MRC Clinical Trials Unit, University College London, London, UK
13Portsmouth Hospitals University NHS Trust, Portsmouth, UK
14Queen Elizabeth University Hospital, NHS Greater Glasgow & Clyde, Glasgow, UK
15Wellcome-MRC Institute of Metabolic Science, Department of Clinical Biochemistry, University of Cambridge, Cambridge, UK
16Cancer Research UK Oxford Centre, University of Oxford, Oxford, UK
Tài liệu tham khảo
Thông tin
Thông tin xuất bản
The Lancet
Tập 398
2258-2276
Thông tin tác giả